This news release describes the outcomes of a small randomized placebo controlled study on the use of N-acetylcysteine, an inexpensive over-the-counter supplement, along with cognitive behavioral therapy in male veterans with PTSD and substance use disorder (SUD). Overall, the release provides a balanced report on the results and the limitations of the study. We think that with the addition of cost and a more in-depth discussion of harms it could have been even better.
Post-traumatic stress is a huge problem among veterans who have seen combat, and the effects of PTSD can be lifelong and debilitating. Since PTSD is also found in police officers, firefighters and other emergency personnel, a safe and effective treatment for it might have wide ranging applications. This trial on a small number of veterans who suffered both from PTSD and substance use disorders could very much add to available therapies in which there are few effective treatments but many sufferers. This could also be significant to the 7 to 8 percent of Americans who develop PTSD at some point in their life.
There is no discussion of the cost of N-acetylcysteine although it is on the World Health Organization’s list of essential medicines, is available over-the-counter and is not very expensive. An online search reveals prices ranging from about $6 for 100 capsules containing 600 mg to around $12 for 50 high-dose capsules containing 700 mg.
The intent of the pilot study was to determine the effect of N-acetylcysteine on PTSD symptoms, cravings and substance use. All three endpoints are described in the news release albeit in relative terms.
We are told that the 8-week trial randomized 35 veterans with PTSD and substance use disorder. Some received N-acetylcysteine and others a placebo, but all of the participants received cognitive behavioral therapy (CBT).
The release reported that “Veterans in the NAC-treated group showed a 46% reduction in PTSD symptoms, compared with a 25% reduction in the placebo group on the Clinical-Administered PTSD Scale (CAPS), which assesses trauma history and symptom severity. The threshold CAPS score for diagnosis of PTSD is 50.”
The release quotes the lead author: “As a group, the NAC-treated veterans were below diagnostic level for PTSD at the end of treatment.” This establishes that the benefit was clinically meaningful. But we prefer to see absolute rather than relative numbers as used here. For example, the actual before and after scores on the PTSD scale would have better illustrated how large the benefit was.
The release explains that the drug used “does not cause side effects at the doses used in the study, but it degrades quickly when stored, is contraindicated in patients with asthma, and can cause nausea at higher doses and so should always be obtained and administered under a physician’s supervision.” However, the published study notes a higher incidence of adverse events in the N-acetylcysteine treated group that in those treated with placebo (66.7% vs. 47.1%). N-acetylcysteine can cause “nausea, vomiting, and diarrhea or constipation. Rarely, it can cause rashes, fever, headache, drowsiness, low blood pressure, and liver problems,” according to WebMD.
This news release does not exaggerate the benefits found in the study, and added helpful caveats about the limitations of the study, its applicability to the general population and its small size.
We’d have preferred to see some specific language cautioning about the short duration of the study (just 8 weeks) and the fact that the results might not hold up over time.
There is no obvious disease-mongering here. However, when the release notes that 7-8 percent of Americans have experienced PTSD at some point in their lives it could have been noted that the PTSD experienced by military veterans — leaving them ‘difficult-to-treat’ — is in a different category than what civilians might experience.
The release clearly states the funding sources and it would be very unlikely that these researchers would have a financial interest in the product under study since it is off-patent and generically available without a prescription.
The news release mentions other treatments for PTSD (such as SSRI antidepressants) even though we don’t learn how effective those treatments are compared to N-acetylcysteine. The lead researcher very helpfully mentions that the drug should not be used without cognitive behavioral therapy or other forms of psychological counseling.
The news release places the results of the study in a positive light noting, “Currently, there are no well-explored pharmacological treatments for patients with co-occurring PTSD/SUD. Although selective serotonin reuptake inhibitors have been approved by the FDA for treatment of PTSD, pharmacological treatments for co-occurring PTSD/SUD have yielded suboptimal results.”
While SSRI’s have been the most studied to date, other drugs that have been studied in preliminary trials could have been mentioned, including prozosin, prazosin, guanfacine, atomoxetine, topiramate, memantine, acamprosate, and ketamine. A 2014 article in Addictive Behaviors journal describes some of these: “Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress.” (Addictive behaviors 39.2 (2014): 428-433.)
We learn it is sold over-the-counter and available everywhere.
The release claims novelty with these statements: “This trial is the first to use NAC as a pharmacotherapy for PTSD and a broad range of SUDs” and “NAC treatment with CBT would be a novel approach to treat co-occurring PTSD and SUD.”
This does appear to be the first such clinical trial of the supplement to address this combination of disorders.
There is no use of unjustifiable language. In fact, we were pleased to see the consistent use of “substance use disorder” or SUD to describe the inappropriate use of illegal and legal drugs. Our recent post on ways to put people first when talking about addiction shows how careful terminology improves accuracy and reduces stigma.
Systematic, Criteria-Driven
I miss @HealthNewsRevu popping up in my feed. Loved seeing this one today.
https://www.healthnewsreview.org/2021/06/zombie-health-care-news/
#healthcare #journalism #ethics #conflictofinterest
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like